The estimated Net Worth of Jolanda Howe is at least $208 Tisíc dollars as of 1 July 2024. Jolanda Howe owns over 1,042 units of Mirum Pharmaceuticals Inc stock worth over $117,390 and over the last few years Jolanda sold MIRM stock worth over $90,730.
Jolanda has made over 6 trades of the Mirum Pharmaceuticals Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Jolanda exercised 1,042 units of MIRM stock worth $43,670 on 1 July 2024.
The largest trade Jolanda's ever made was selling 3,459 units of Mirum Pharmaceuticals Inc stock on 25 August 2023 worth over $90,730. On average, Jolanda trades about 1,804 units every 52 days since 2023. As of 1 July 2024 Jolanda still owns at least 2,801 units of Mirum Pharmaceuticals Inc stock.
You can see the complete history of Jolanda Howe stock trades at the bottom of the page.
Jolanda's mailing address filed with the SEC is C/O MIRUM PHARMACEUTICALS, INC., 989 E HILLSDALE BLVD., SUITE 300, FOSTER CITY, CA, 94404.
Over the last 5 years, insiders at Mirum Pharmaceuticals Inc have traded over $10,912,565 worth of Mirum Pharmaceuticals Inc stock and bought 7,735,045 units worth $117,972,829 . The most active insiders traders include Forest Baskett, Scott D Sandell a Anthony A. Jr. Florence. On average, Mirum Pharmaceuticals Inc executives and independent directors trade stock every 24 days with the average trade being worth of $4,538,937. The most recent stock trade was executed by Patrick J Heron on 6 September 2024, trading 230 units of MIRM stock currently worth $9,563.
mirum pharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. its lead product candidate is maralixibat, an investigational oral drug that is in phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of alagille syndrome and biliary atresia disease. the company is also develops volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. mirum pharmaceuticals, inc. was founded in 2018 and is headquartered in foster city, california.
Mirum Pharmaceuticals Inc executives and other stock owners filed with the SEC include: